BioSpace News Archive

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application for fezolinetant, an investigational oral, nonhormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.

Jemincare, a leading pharmaceutical company from China, announced that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.

On May 19th, the European Medicines Agency announced that it had adopted a positive opinion regarding the application for conditional approval of Kinpeygo® for the treatment of IgA nephropathy, and on July 15th the European Commission issued the market authorization for Kinpeygo in the European Economic Area.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its half-year and second quarter financial results for the periods ended June 30, 2022 and provided a corporate update.

iZafe Group AB has signed a Letter of Intent with Pilloxa AB regarding the acquisition of 100 percent of the shares in Pilloxa.

Royal Philips convenes an Extraordinary General Meeting of Shareholders and publishes the agenda with explanatory note.

The Company’s revenue increased 113.7% YoY to RMB 1.53 billion in the first six months of 2022.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that it has signed an agreement to acquire Positron Precision GmbH, a company developing a technology platform for positron emission tomography tracers and various radiotherapeutic candidates.

CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and medical devices, was recently granted a CE Mark certificate for two of the company’s monkeypox diagnostic tests.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.